Simpkins, F., Leary, A., Willmott, L., Monk, B., FRENEL, J.-S., Starks, D., … Backes, F. (2025). Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066). In Gynecologic Oncology (Vol. 200, pp. 8–9). Elsevier BV. https://doi.org/10.1016/j.ygyno.2025.03.060

Simpkins, Fiona, Alexandra Leary, Lyndsay Willmott, Bradley Monk, Jean-Sebastien FRENEL, David Starks, Meena Okera, et al. “Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066).” In Gynecologic Oncology, 200:8–9. Elsevier BV, 2025. https://doi.org/10.1016/j.ygyno.2025.03.060.

Simpkins F, Leary A, Willmott L, Monk B, FRENEL J-S, Starks D, et al. Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066). In: Gynecologic Oncology. Elsevier BV; 2025. p. 8–9.

Simpkins, Fiona, et al. “Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066).” Gynecologic Oncology, vol. 200, Elsevier BV, 2025, pp. 8–9. Crossref, doi:10.1016/j.ygyno.2025.03.060.

Simpkins F, Leary A, Willmott L, Monk B, FRENEL J-S, Starks D, Okera M, Secord AA, O’Malley D, Martin L, Ouali K, Oehler M, GOH J, Slomovitz B, Lim P, Shannon C, Neff R, Kim D, Li H, Jandial D, Backes F. Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066). Gynecologic Oncology. Elsevier BV; 2025. p. 8–9.